Ingenia Therapeutics950260
Ingenia Therapeutics (950260) Material Information, Oct 27, 2026
Filing date ·
Ingenia Therapeutics said the U.S. FDA approved the IND for IGT-303 in a Phase 1/2a clinical trial, according to a filing on October 27, 2026.
Sign in to read this filing in detail
Continue to the filing details and any available analysis after signing in.
Filing lists and official source links are available without signing in.